vs
吉利德科学（GILD）与Raymond James Financial（RJF）财务数据对比。点击上方公司名可切换其他公司
吉利德科学的季度营收约是Raymond James Financial的2.1倍（$7.9B vs $3.9B），吉利德科学净利率更高（27.5% vs 14.1%，领先13.4%），Raymond James Financial同比增速更快（13.0% vs 4.7%），过去两年吉利德科学的营收复合增速更高（8.9% vs 1.3%）
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
雷蒙德詹姆斯金融是美国跨国独立投资银行及金融服务机构，通过旗下子公司为个人、企业及市政主体提供多元金融服务，核心业务覆盖投资与财务规划、投资银行、资产管理等领域，总部位于美国佛罗里达州圣彼得堡。
GILD vs RJF — 直观对比
营收规模更大
GILD
是对方的2.1倍
$3.9B
营收增速更快
RJF
高出8.3%
4.7%
净利率更高
GILD
高出13.4%
14.1%
两年增速更快
GILD
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $7.9B | $3.9B |
| 净利润 | $2.2B | $544.0M |
| 毛利率 | 79.5% | — |
| 营业利润率 | 25.0% | — |
| 净利率 | 27.5% | 14.1% |
| 营收同比 | 4.7% | 13.0% |
| 净利润同比 | 22.4% | 10.0% |
| 每股收益（稀释后） | $1.75 | $2.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GILDRJF
| Q1 26 | — | $3.9B | ||
| Q4 25 | $7.9B | $4.2B | ||
| Q3 25 | $7.8B | $4.2B | ||
| Q2 25 | $7.1B | $3.8B | ||
| Q1 25 | $6.7B | $3.8B | ||
| Q4 24 | $7.6B | $4.0B | ||
| Q3 24 | $7.5B | $4.0B | ||
| Q2 24 | $7.0B | $3.8B |
净利润GILDRJF
| Q1 26 | — | $544.0M | ||
| Q4 25 | $2.2B | $563.0M | ||
| Q3 25 | $3.1B | $604.0M | ||
| Q2 25 | $2.0B | $436.0M | ||
| Q1 25 | $1.3B | $495.0M | ||
| Q4 24 | $1.8B | $600.0M | ||
| Q3 24 | $1.3B | $602.0M | ||
| Q2 24 | $1.6B | $492.0M |
毛利率GILDRJF
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 79.8% | — | ||
| Q2 25 | 78.8% | — | ||
| Q1 25 | 76.9% | — | ||
| Q4 24 | 79.1% | — | ||
| Q3 24 | 79.1% | — | ||
| Q2 24 | 77.8% | — |
营业利润率GILDRJF
| Q1 26 | — | — | ||
| Q4 25 | 25.0% | — | ||
| Q3 25 | 42.8% | — | ||
| Q2 25 | 34.9% | 14.7% | ||
| Q1 25 | 33.6% | 17.5% | ||
| Q4 24 | 32.4% | 18.6% | ||
| Q3 24 | 11.8% | — | ||
| Q2 24 | 38.0% | 17.1% |
净利率GILDRJF
| Q1 26 | — | 14.1% | ||
| Q4 25 | 27.5% | 13.5% | ||
| Q3 25 | 39.3% | 14.4% | ||
| Q2 25 | 27.7% | 11.3% | ||
| Q1 25 | 19.7% | 12.9% | ||
| Q4 24 | 23.6% | 14.9% | ||
| Q3 24 | 16.6% | 15.0% | ||
| Q2 24 | 23.2% | 13.1% |
每股收益（稀释后）GILDRJF
| Q1 26 | — | $2.83 | ||
| Q4 25 | $1.75 | $2.79 | ||
| Q3 25 | $2.43 | $2.96 | ||
| Q2 25 | $1.56 | $2.12 | ||
| Q1 25 | $1.04 | $2.36 | ||
| Q4 24 | $1.43 | $2.86 | ||
| Q3 24 | $1.00 | $2.85 | ||
| Q2 24 | $1.29 | $2.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.0M | $5.4B |
| 总债务越低越好 | $24.9B | — |
| 股东权益账面价值 | $22.7B | $52.0M |
| 总资产 | $59.0B | $91.9B |
| 负债/权益比越低杠杆越低 | 1.10× | — |
8季度趋势，按日历期对齐
现金及短期投资GILDRJF
| Q1 26 | — | $5.4B | ||
| Q4 25 | $68.0M | $9.9B | ||
| Q3 25 | $19.0M | $11.4B | ||
| Q2 25 | $69.0M | $9.2B | ||
| Q1 25 | — | $9.7B | ||
| Q4 24 | — | $10.0B | ||
| Q3 24 | — | $11.0B | ||
| Q2 24 | — | $9.1B |
总债务GILDRJF
| Q1 26 | — | — | ||
| Q4 25 | $24.9B | — | ||
| Q3 25 | $24.9B | — | ||
| Q2 25 | $24.9B | — | ||
| Q1 25 | $25.0B | — | ||
| Q4 24 | $26.7B | — | ||
| Q3 24 | $23.2B | — | ||
| Q2 24 | $23.3B | — |
股东权益GILDRJF
| Q1 26 | — | $52.0M | ||
| Q4 25 | $22.7B | $12.6B | ||
| Q3 25 | $21.5B | $12.5B | ||
| Q2 25 | $19.7B | $12.3B | ||
| Q1 25 | $19.2B | $12.2B | ||
| Q4 24 | $19.3B | $11.9B | ||
| Q3 24 | $18.5B | $11.7B | ||
| Q2 24 | $18.3B | $11.2B |
总资产GILDRJF
| Q1 26 | — | $91.9B | ||
| Q4 25 | $59.0B | $88.8B | ||
| Q3 25 | $58.5B | $88.2B | ||
| Q2 25 | $55.7B | $84.8B | ||
| Q1 25 | $56.4B | $83.1B | ||
| Q4 24 | $59.0B | $82.3B | ||
| Q3 24 | $54.5B | $83.0B | ||
| Q2 24 | $53.6B | $80.6B |
负债/权益比GILDRJF
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.16× | — | ||
| Q2 25 | 1.27× | — | ||
| Q1 25 | 1.30× | — | ||
| Q4 24 | 1.38× | — | ||
| Q3 24 | 1.26× | — | ||
| Q2 24 | 1.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | — |
| 自由现金流经营现金流 - 资本支出 | $3.1B | — |
| 自由现金流率自由现金流/营收 | 39.4% | — |
| 资本支出强度资本支出/营收 | 2.6% | — |
| 现金转化率经营现金流/净利润 | 1.52× | — |
| 过去12个月自由现金流最近4个季度 | $9.5B | — |
8季度趋势，按日历期对齐
经营现金流GILDRJF
| Q1 26 | — | — | ||
| Q4 25 | $3.3B | $-10.0M | ||
| Q3 25 | $4.1B | $796.0M | ||
| Q2 25 | $827.0M | $691.0M | ||
| Q1 25 | $1.8B | $117.0M | ||
| Q4 24 | $3.0B | $830.0M | ||
| Q3 24 | $4.3B | $510.0M | ||
| Q2 24 | $1.3B | $711.0M |
自由现金流GILDRJF
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $-56.0M | ||
| Q3 25 | $4.0B | $752.0M | ||
| Q2 25 | $720.0M | $634.0M | ||
| Q1 25 | $1.7B | $71.0M | ||
| Q4 24 | $2.8B | $789.0M | ||
| Q3 24 | $4.2B | $460.0M | ||
| Q2 24 | $1.2B | $655.0M |
自由现金流率GILDRJF
| Q1 26 | — | — | ||
| Q4 25 | 39.4% | -1.3% | ||
| Q3 25 | 51.0% | 17.9% | ||
| Q2 25 | 10.2% | 16.5% | ||
| Q1 25 | 24.8% | 1.8% | ||
| Q4 24 | 37.4% | 19.6% | ||
| Q3 24 | 55.2% | 11.5% | ||
| Q2 24 | 17.2% | 17.4% |
资本支出强度GILDRJF
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 1.1% | ||
| Q3 25 | 1.9% | 1.1% | ||
| Q2 25 | 1.5% | 1.5% | ||
| Q1 25 | 1.6% | 1.2% | ||
| Q4 24 | 1.9% | 1.0% | ||
| Q3 24 | 1.9% | 1.2% | ||
| Q2 24 | 1.9% | 1.5% |
现金转化率GILDRJF
| Q1 26 | — | — | ||
| Q4 25 | 1.52× | -0.02× | ||
| Q3 25 | 1.35× | 1.32× | ||
| Q2 25 | 0.42× | 1.58× | ||
| Q1 25 | 1.34× | 0.24× | ||
| Q4 24 | 1.67× | 1.38× | ||
| Q3 24 | 3.44× | 0.85× | ||
| Q2 24 | 0.82× | 1.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
RJF
| Private Client Group | $2.8B | 73% |
| Bank | $486.0M | 13% |
| Capital Markets | $464.0M | 12% |
| Other | $99.0M | 3% |
